{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "MISS",
      "answer": "pred ~$4.55B vs. cons $4.61B",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q2 2026 adjusted EBIT",
      "prediction": "MISS",
      "answer": "pred ~$1.13B vs. cons $1.15B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "MISS",
      "answer": "pred ~$1.98 vs. cons $2.01",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Organic sales growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~8.0% midpoint vs. cons 8.0% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adjusted EBIT",
      "prediction": "BETTER",
      "answer": "guide ~$4.70B midpoint vs. cons $4.66B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Free cash flow",
      "prediction": "LOWER",
      "answer": "guide ~$1.25B midpoint vs. cons $1.30B (2H2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.2,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Q2 revenue and adjusted EBIT misses of roughly 1.3%-1.7%, combined with unchanged ~8.0% FY2026 organic-growth guidance, leave a low-double-digit 2H growth requirement; the ~$1.25B 2H2026 FCF guide versus ~$1.30B consensus should drive modest estimate cuts after an initial -2.8% residual move, extending the five-day residual to -4.2%.",
  "day5_confidence": "MEDIUM"
}